Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial

Bone Marrow Transplantation volume 34, pages 577–580 (2004)Cite this article

Summary:

Relapse of hematologic malignancies after allogeneic stem cell transplantation remains a common problem, in particular for patients who have advanced disease at the time of transplantation. Thiotepa has excellent antileukemic and immunosuppressive activity, and could therefore be a useful drug in the conditioning regimen for patients with advanced hematologic neoplasms. We retrospectively analyzed toxicity, engraftment and survival data of 41 patients who received a conditioning regimen of thiotepa (600 mg/m2) and hyperfractionated TBI (10 Gy) prior to matched related (n=25) or matched unrelated (n=16) allogeneic stem cell transplantation. The mean age at transplantation was 37.8 years (range 20–59), all but five patients had advanced hematologic malignancies at the time of transplantation. GVHD prophylaxis was with standard cyclosporine and methotrexate. Engraftment was excellent, but the regimen was associated with a high incidence of grade III renal (41%) and hepatic (15%) toxicity, and high transplant-related mortality (44% at day +90). The 3-year event-free survival was 13% and overall survival 14%. We conclude that this regimen requires modification to reduce toxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Alyea E, Neuberg D, Mauch P et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002; 8: 139–144.

    Article  CAS  Google Scholar 

  2. Bieri S, Helg C, Chapuis B et al. Total body irradiation before allogeneic bone marrow transplantation: is more better? Int J Radiat Oncol Biol Phys 2001; 49: 1071–1077.

    Article  CAS  Google Scholar 

  3. Giralt S, LeMaistre C, Vriesendorp H et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 1994; 12: 1923–1930.

    Article  CAS  Google Scholar 

  4. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17–26.

    Article  CAS  Google Scholar 

  5. Wolff S, Herzig R, Herzig G . High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17: 2–6.

    CAS  Google Scholar 

  6. Bacigalupo A, Lint MV, Valbonesi M et al. Thiotepa cyclophosphamide followed by granulocyte-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood 1996; 88: 353–357.

    CAS  Google Scholar 

  7. Kletzel M, Abella E, Sandler E et al. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and Marrow Transplant Consortium. J Pediatr Hematol Oncol 1998; 20: 49–54.

    Article  CAS  Google Scholar 

  8. Van Besien K, Devine S, Wickrema A et al. Safety and outcome after fludarabine–thiotepa–TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant 2003; 32: 9–13.

    Article  CAS  Google Scholar 

  9. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  10. Wilson WH, Jain N, Bryant G et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 1992; 10: 1712–1722.

    Article  CAS  Google Scholar 

  11. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    Article  CAS  Google Scholar 

  12. Zecca M, Pession A, Messina C et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol 1999; 17: 1838–1846.

    Article  CAS  Google Scholar 

  13. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: the role of gastro-intestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.

    CAS  Google Scholar 

  14. Bacigalupo A, Lamparelli T, Bruzzi P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Nebraska Medical Center, Omaha, NE, USA

    M P Devetten

  2. MD Anderson Cancer Center, Houston, TX, USA

    M H Qazilbash

  3. Blood and Marrow Transplantation Program, West Virginia University Hospital, Morgantown, WV, USA

    C L Beall, P Bunner, R Weisenborn & S G Ericson

  4. Oklahoma Oncology, Tulsa, OK, USA

    J P Lynch

Authors
  1. M P Devetten
    View author publications

    Search author on:PubMed Google Scholar

  2. M H Qazilbash
    View author publications

    Search author on:PubMed Google Scholar

  3. C L Beall
    View author publications

    Search author on:PubMed Google Scholar

  4. P Bunner
    View author publications

    Search author on:PubMed Google Scholar

  5. R Weisenborn
    View author publications

    Search author on:PubMed Google Scholar

  6. J P Lynch
    View author publications

    Search author on:PubMed Google Scholar

  7. S G Ericson
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to M P Devetten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Devetten, M., Qazilbash, M., Beall, C. et al. Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. Bone Marrow Transplant 34, 577–580 (2004). https://doi.org/10.1038/sj.bmt.1704642

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704642

Keywords

This article is cited by

Search

Advanced search

Quick links